When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault.
The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic exposure from legacy CAR-T methodologies.
With few catalysts until a readout from a first-line combination therapy Phase 1 trial near YE22, the recent insider buying merited a deeper dive.
A full investment analysis follows in the paragraphs below.